Latest revenue
$32.0K
as of 2026-03-31
Latest net income
$-4.3M
as of 2026-03-31
Net margin
-13406.3%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $196.6M
- Enterprise value
- $196.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $8.51
- 52-wk low
- $2.33
- Beta
- —
- Shares out
- 32.3M
5-year trend
What this company does
Item 1. Business. Overview We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category. We are developing molecular diagnostic test kits designed to empower our customers to run their own tests in-house to participate in the patient-care value chain, which is counter-positioned with the send-out-testing central laboratory model. Our decentralized approach also puts testing in the hands of researchers to enable more studies, which we believe can improve standards of care while also creating demand for more testing. We believe that combining innovative science…
AI summary unavailable — showing raw filing excerpt
Generated from IMDX's filing dated 2026-03-26
Key risks
Item 1A. Risk Factors. Our business is subject to various risks, including those described below. The risks below are those that we believe are the material risks that we currently face but are not the only risks facing us and our business. You should consider the following risk factors, together with all of the other information included in this Report, which could materially adversely affect our proposed operations, our business prospects, our financial condition, and the value of an investment in our business. If any of the following risks, either alone or taken together, or other risks not presently known to us or that we currently believe to not be significant, develop into actual…
AI summary unavailable — showing raw filing excerpt
Generated from IMDX's filing dated 2026-03-26
Profitability
Gross margin
56.7%
44.1%Operating margin
-1260.8%
61.1%Net margin
-1238.5%
61.6%Return on equity
159.6%
67.7%Return on assets
-195.0%
12.8%Leverage
Debt / equity
-1.82×
52.9%Debt / assets
222.2%
64.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $32.0K | -98.5% | $-4.3M | +35.7% | -13406.3% |
Q4 2025 2025-12-31 | $1.1M | -23.4% | $-23.0M | +31.5% | -2015.4% |
Q3 2025 2025-09-30 | $260.0K | +126.1% | $-10.9M | +19.6% | -4174.6% |
Q2 2025 2025-06-30 | $518.0K | +398.1% | $-9.7M | -115.1% | -1880.7% |
Q1 2025 2025-03-31 | $2.1M | +1114.8% | $-6.7M | +26.9% | -312.0% |
Q4 2024 2024-12-31 | $1.5M | — | $-33.5M | — | -2255.1% |
Q3 2024 2024-09-30 | $115.0K | -73.2% | $-13.5M | -107.9% | -11733.0% |
Q2 2024 2024-06-30 | $104.0K | -77.5% | $-4.5M | +14.5% | -4355.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on IMDX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$5.7M
Insider selling
$0
Net activity
+$5.7M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns IMDX
Institutional value
$6.3M
Total shares held
2.2M
Distinct holders
20
-15 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | PURA VIDA INVESTMENTS, LLC | 947.1K | $3.1M | +0 (+0.0%) | No change |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 537.2K | $1.8M | — | New |
| 3 | BlackRock, Inc. | 135.3K | $443.9K | +4.0K (+3.0%) | Added |
| 4 | VANGUARD FIDUCIARY TRUST CO | 132.6K | $434.9K | — | New |
| 5 | Family Office Research LLC | 127.3K | $417.4K | — | New |
| 6 | UBS Group AG | 22.8K | $74.6K | +19.8K (+673.6%) | Added |
| 7 | Flatrock Wealth Partners LLC | 13.0K | $42.8K | — | New |
| 8 | Private Advisor Group, LLC | 10.4K | $34.2K | +0 (+0.0%) | No change |
| 9 | Vanguard Global Advisers, LLC | 5.8K | $18.9K | — | New |
| 10 | CITIGROUP INC | 815 | $2.7K | +814 (+81400.0%) | Added |
| 11 | Golden State Equity Partners | 450 | $1.5K | — | New |
| 12 | FNY Investment Advisers, LLC | 247.4K | $811 | +206.8K (+509.7%) | Added |
| 13 | SBI Securities Co., Ltd. | 185 | $607 | +0 (+0.0%) | No change |
| 14 | JPMORGAN CHASE & CO | 154 | $393 | +0 (+0.0%) | No change |
| 15 | BNP PARIBAS FINANCIAL MARKETS | 64 | $210 | +34 (+113.3%) | Added |
| 16 | Piscataqua Savings Bank | 25 | $81 | +0 (+0.0%) | No change |
| 17 | Cassaday & Co Wealth Management LLC | 10 | $33 | — | New |
| 18 | ALBION FINANCIAL GROUP /UT | 7 | $23 | +0 (+0.0%) | No change |
| 19 | Caitong International Asset Management Co., Ltd | 1 | $3 | — | New |
| 20 | Farther Finance Advisors, LLC | 1 | $3 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once IMDX's latest filing finishes processing.